Scholarlink

<p><i>Paeoniae Radix Rubra</i> (Chishao, CS) and <i>Moutan Cortex</i> (Mudanpi, MDP) are frequently utilized in the clinical management of SLE, yet the molecular mechanisms underlying their therapeutic effects in SLE remain to be fully elucidated. This study aims to investigate the mechanism of CS-MDP in treating SLE using a network pharmacology and experimental approach. The potential active ingredients and targets of CS-MDP were obtained through screening the TCMSP database. Known targets of SLE were retrieved from disease databases, and the intersection targets of CS-MDP in treating SLE were obtained using the Venny 2.1.0 online platform. Network enrichment analysis of the intersection targets was performed using R 4.0.5 software. Molecular docking of the core ingredients and targets was carried out using AutoDock Vina 1.1.2. Finally, the mechanism of CS-MDP against SLE was verified through in vivo and in vitro experiments. CS-MDP was found to have 21 potential active ingredients and 208 targets. A total of 111 intersection targets were determined for CS-MDP in treating SLE. GO enrichment analysis identified 1987 terms, mainly enriched in cellular response to chemical stress and regulation of peptide secretion. KEGG analysis identified 185 signaling pathways, with main enrichments in Lipid and atherosclerosis, and Hepatitis B. In vitro, CS-MDP inhibited the mRNA expression of TNF-α, IL-1β, and IL-6, and downregulated the protein expression of the NF-κB signaling pathway in LPS-challenged RAW264.7 cells. In addition, CS-MDP also downregulated the protein expression of the NF-κB signaling pathway in MRL/lpr lupus mice. In conclusion, this study suggests that CS-MDP may exert therapeutic effects on SLE, potentially by modulating the NF-κB signaling pathway and consequently inhibiting the expression of pro-inflammatory cytokines.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Network pharmacology and experimental analysis of Paeoniae radix Rubra and moutan cortex for SLE treatment

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年6月25日

查看全文
  • Fangzhi Wei,
  • Minyu Zeng,
  • Wei Liu,
  • Shiyu Hou,
  • Shumin Sun,
  • Yiji Xing,
  • Yi Liu,
  • Mengqi Zhang,
  • Aimin Gong,
  • ShuDian Lin,
  • Ying Liu

摘要

Paeoniae Radix Rubra (Chishao, CS) and Moutan Cortex (Mudanpi, MDP) are frequently utilized in the clinical management of SLE, yet the molecular mechanisms underlying their therapeutic effects in SLE remain to be fully elucidated. This study aims to investigate the mechanism of CS-MDP in treating SLE using a network pharmacology and experimental approach. The potential active ingredients and targets of CS-MDP were obtained through screening the TCMSP database. Known targets of SLE were retrieved from disease databases, and the intersection targets of CS-MDP in treating SLE were obtained using the Venny 2.1.0 online platform. Network enrichment analysis of the intersection targets was performed using R 4.0.5 software. Molecular docking of the core ingredients and targets was carried out using AutoDock Vina 1.1.2. Finally, the mechanism of CS-MDP against SLE was verified through in vivo and in vitro experiments. CS-MDP was found to have 21 potential active ingredients and 208 targets. A total of 111 intersection targets were determined for CS-MDP in treating SLE. GO enrichment analysis identified 1987 terms, mainly enriched in cellular response to chemical stress and regulation of peptide secretion. KEGG analysis identified 185 signaling pathways, with main enrichments in Lipid and atherosclerosis, and Hepatitis B. In vitro, CS-MDP inhibited the mRNA expression of TNF-α, IL-1β, and IL-6, and downregulated the protein expression of the NF-κB signaling pathway in LPS-challenged RAW264.7 cells. In addition, CS-MDP also downregulated the protein expression of the NF-κB signaling pathway in MRL/lpr lupus mice. In conclusion, this study suggests that CS-MDP may exert therapeutic effects on SLE, potentially by modulating the NF-κB signaling pathway and consequently inhibiting the expression of pro-inflammatory cytokines.